Company Description

Liminatus Pharma, Inc. operates as a pre-clinical stage biopharmaceutical company that develops novel cancer therapies.

It is developing CD47, a high affinity humanized anti CD47 antibody that has the potential to translate into clinic for CD47 SIRPα blocking and restoring the anti-tumor function of innate immune cells without inducing hemagglutination or hemolysis.

The company was founded in 2018 is based in LA Palma, California.

Liminatus Pharma, Inc.

Country	United States
Founded	2018
Industry	Biotechnology
Sector	Healthcare
CEO	Chris Kim

Contact Details

Address: 6 Centerpointe Drive, #625 La Palma, California 90623 United States
Phone	213 273 5453
Website	liminatuspharma.com

Stock Details

Ticker Symbol	LIMN
Exchange	NASDAQ
Stock Type	Common Stock
Fiscal Year	January - December
Reporting Currency	USD
CIK Code	0001831874
ISIN Number	US53271X1081

Key Executives

Name	Position
Chris Kim J.D., L.L.M.	Chief Executive Officer, Treasurer and Secretary